Among patients with hormone-sensitive prostate cancer, circulating tumor cell (CTC) count at the start of treatment may be able to indicate which patients are likely to live longer after treatment, as well as those who may be good candidates for novel therapies and clinical trial enrollment, researchers have found.

Increasing percentages of some older U.S. men with intermediate-risk and high-risk prostate cancers are undergoing treatments that carry risks of side effects that can significantly reduce the quality of life without extending life, according to a new study led by Cedars-Sinai.

The Community Oncology Alliance (COA) launched two new local chapters of its Patient Advocacy Network (CPAN) this week. The Center for Cancer and Blood Disorders in Bethesda, MD, and Oncology/Hematology of Loudoun and Reston in Lansdowne, VA, joined the ranks of practices who are educating and empowering patients, survivors, caregivers, and other advocates on the importance of using your own voice to support independent community oncology and its patients.

Earlier this year, the Federal Trade Commission (FTC) announced that it had begun taking legal action against the three largest pharmacy benefit managers (PBMs), the third-party companies that manage prescription drug benefits for health insurance companies and employers.

In recent years, considerable progress has been made in the early detection and treatment of lung cancer.

Adding specialty infusion services to an oncology practice may provide new opportunities to offer comprehensive care and other benefits to patients while practices gain new revenue streams.

Because of his job as a dermatologist, Dr Deshan Sebaratnam frequently gets asked questions by friends, family and strangers about skin treatments.

Cancer occurs when genetic changes disrupt cells’ normal functions.

Tattoos are often seen as powerful expressions of individuality. In the medical world, however, they can serve as unwanted reminders of a difficult past.

Researchers from the Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine, and the Fielding School of Public Health at the University of California, Los Angeles (UCLA) were awarded a $2.5 million grant from the independent charitable organization Bristol Myers Squibb Foundation to establish a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County.